Clinical Trial Update: AK104 for Recurrent or Metastatic Vulvar Cancer [Phase 2]

View source ↗

Summary

This clinical trial update indicates that AK104 is being studied in a Phase 2 trial for recurrent or metastatic vulvar cancer and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvar Cancer

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)

Snippet

Sponsor: Akeso | Conditions: Vulvar Cancer | Phase 2 | Status: RECRUITING